Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed

[Figure: see text]

Detalles Bibliográficos
Autores principales: Zhou, Dao, Fan, Jiaqi, Liu, Xianbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877208/
https://www.ncbi.nlm.nih.gov/pubmed/36713757
http://dx.doi.org/10.1016/j.jacasi.2022.09.008
_version_ 1784878318716190720
author Zhou, Dao
Fan, Jiaqi
Liu, Xianbao
author_facet Zhou, Dao
Fan, Jiaqi
Liu, Xianbao
author_sort Zhou, Dao
collection PubMed
description [Figure: see text]
format Online
Article
Text
id pubmed-9877208
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98772082023-01-27 Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed Zhou, Dao Fan, Jiaqi Liu, Xianbao JACC Asia Original Research [Figure: see text] Elsevier 2022-12-15 /pmc/articles/PMC9877208/ /pubmed/36713757 http://dx.doi.org/10.1016/j.jacasi.2022.09.008 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Zhou, Dao
Fan, Jiaqi
Liu, Xianbao
Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
title Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
title_full Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
title_fullStr Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
title_full_unstemmed Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
title_short Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed
title_sort rivaroxaban monotherapy for atrial fibrillation and coronary artery disease in underweight/obese patients: evidence is needed
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877208/
https://www.ncbi.nlm.nih.gov/pubmed/36713757
http://dx.doi.org/10.1016/j.jacasi.2022.09.008
work_keys_str_mv AT zhoudao rivaroxabanmonotherapyforatrialfibrillationandcoronaryarterydiseaseinunderweightobesepatientsevidenceisneeded
AT fanjiaqi rivaroxabanmonotherapyforatrialfibrillationandcoronaryarterydiseaseinunderweightobesepatientsevidenceisneeded
AT liuxianbao rivaroxabanmonotherapyforatrialfibrillationandcoronaryarterydiseaseinunderweightobesepatientsevidenceisneeded

Ejemplares similares